Connect with us

Public Companies

Seelos Therapeutics to Sponsor and Participate in Wonderland, the World’s Leading Psychedelic Event

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system…

Published

on

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will sponsor and participate in Wonderland, the World’s Leading Psychedelic Event, organized by Microdose Psychedelics Insights, to be held at the Mana Wynwood Convention Center in Miami, FL from November 3rd to the 5th

Seelos will sponsor the Press Breakfast with Seelos Therapeutics on Friday November 4th at 8:30am ET to discuss their SLS-002 (intranasal racemic ketamine) program, which is currently enrolling patients in Part 2 of the registration directed, randomized, double-blind, placebo-controlled clinical study. The purpose of the study is to evaluate the efficacy, safety, and tolerability of repeat doses of SLS-002, in addition to standard of care, on the symptoms of major depression and suicidality in patients who are assessed to be at an imminent risk of suicide.

Additionally, Seelos will participate in a panel discussion titled: Route of Administration Dose; Does Dissociation Correlate with Antidepressant/Analgesic Effects on Saturday, November 5th at 10:40am ET.

Also, on Saturday at 1:10pm ET, Raj Mehra, Ph.D., Chairman and CEO of Seelos and Tim Whitaker, M.D., Chief Medical Officer of Seelos, will be interviewed by Dean Burnett, Ph.D., in a fireside chat titled:  Seelos Therapeutics: Novel Investigational Program to Address Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson’s disease, other psychiatric and movement disorders plus orphan diseases.

Read More

Trending

 

NXTpsychedelics is part of NXT Financial Media Group. Copyright 2021 NXT.financial media